日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Acute effects of a single bout of high-intensity strength and endurance exercise on cognitive biomarkers in young adults and elderly men: a within-subjects crossover study

单次高强度力量和耐力训练对青年人和老年男性认知生物标志物的急性影响:一项受试者内交叉研究

Bekkos, Carolin Haberstroh; Sujan, Md Abu Jafar; Stunes, Astrid Kamilla; Tari, Atefe Rafiee; Aagård, Norun; Brobakken, Cathrine Langlie; Brevig, Martin Siksjø; Syversen, Unni; Wang, Eivind; Mosti, Mats Peder

Advancing measurement-based care through triangle of care: Development and feasibility of the Transdiagnostic Global Impression - Psychopathology scale for patients and informants

通过照护三角推进基于测量结果的照护:跨诊断总体印象-精神病理学量表(适用于患者和知情者)的开发和可行性研究

McIntyre, Roger S; Dombi, Zsofia Borbala; Barabassy, Agota; Brevig, Thomas; Németh, György; Correll, Christoph U

Risk factors for migraine disease progression: a narrative review for a patient-centered approach

偏头痛疾病进展的风险因素:以患者为中心的叙述性综述

Lipton, Richard B; Buse, Dawn C; Nahas, Stephanie J; Tietjen, Gretchen E; Martin, Vincent T; Löf, Elin; Brevig, Thomas; Cady, Roger; Diener, Hans-Christoph

Interhospital variability in failure to rescue rates following aortic valve surgery

主动脉瓣膜手术后抢救失败率的医院间差异

Bauer, Tyler M; Pienta, Michael; Wu, Xiaoting; Lehr, Eric J; Whitman, Glenn J R; Kramer, Robert S; Brevig, James; Pagani, Francis D; Likosky, Donald S

Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials

对接受 eptinezumab 治疗且疗效≥75% 的患者,其患者报告结局、健康相关生活质量和急性用药情况:PROMISE 试验的亚组汇总分析

Lipton, Richard B; Charleston, Larry 4th; Tassorelli, Cristina; Brevig, Thomas; Hirman, Joe; Cady, Roger

Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine

对eptinezumab的早期反应表明慢性偏头痛患者持续反应的可能性很高

Buse, Dawn C; Winner, Paul K; Charleston, Larry 4th; Hirman, Joe; Cady, Roger; Brevig, Thomas

Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study

接受eptinezumab治疗的慢性偏头痛患者急性头痛药物使用量的变化:PROMISE-2研究的亚组分析

Cowan, Robert P; Marmura, Michael J; Diener, Hans-Christoph; Starling, Amaal J; Schim, Jack; Hirman, Joe; Brevig, Thomas; Cady, Roger

Acute Effects of Strength and Endurance Training on Bone Turnover Markers in Young Adults and Elderly Men

力量和耐力训练对青年人和老年男性骨转换标志物的急性影响

Astrid Kamilla Stunes, Cathrine Langlie Brobakken, Md Abu Jafar Sujan, Norun Aagård, Martin Siksjø Brevig, Eivind Wang, Unni Syversen, Mats Peder Mosti

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials

eptinezumab治疗偏头痛患者的安全性和耐受性:5项临床试验的汇总分析

Smith, Timothy R; Spierings, Egilius L H; Cady, Roger; Hirman, Joe; Schaeffler, Barbara; Shen, Vivienne; Sperling, Bjørn; Brevig, Thomas; Josiassen, Mette Krog; Brunner, Elizabeth; Honeywell, Loan; Mehta, Lahar

Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials

更正:eptinezumab治疗偏头痛患者的安全性和耐受性:5项临床试验的汇总分析

Smith, Timothy R; Spierings, Egilius L H; Cady, Roger; Hirman, Joe; Schaeffler, Barbara; Shen, Vivienne; Sperling, Bjørn; Brevig, Thomas; Josiassen, Mette Krog; Brunner, Elizabeth; Honeywell, Loan; Mehta, Lahar